Drugs / azetimibe
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07611747 Background | Apr 2026 → Apr 2031 expected | atherosclerosis, carotid artery disorder, psoriatic arthritis, spondyloarthropathy +1 | Marqués de Valdecilla Research Institute (IDIVAL) | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | azetimibe | “Treatment includes high-intensity statins (atorvastatin 40-80mg, rouvastatin 20-40mg), with possible addition of azetimibe, bempedoic acid, and/or PCSK9 inhibitors if target is...” NCT07611747 ↗ |